TKI and Immunotherapy Combo Efforts in RCC Remain of Interes

Final outcomes from the phase 1b/2 Study 111/KEYNOTE-146 trial, evaluating treatment with lenvatinib and pembrolizumab in patients with advanced renal cell carcinoma, has sparked interest in the use of this combination.

Related Keywords

Memorial Sloan Kettering Cancer Center , New York , United States , Boston , Massachusetts , Chan Lee , , Kidney Cancer Research Summit , Chung Han Lee , Cancer Research Summit , Keynote 146 , Lenvatinib , Pembrolizumab , Advanced Rcc , Nct02501096 ,